Related Experiment Videos
A model for compounds active against human rhinovirus-14 based on X-ray crystallography data
G D Diana1, A M Treasurywala, T R Bailey
1Sterling Research Group, Rensselaer, New York 12144.
Journal of Medicinal Chemistry
|May 1, 1990
Summary
Researchers developed a model to understand how (oxazolinylphenyl)isoxazoles fight human rhinovirus-14 (HRV-14). Active compounds fit specific binding sites, while inactive ones are too bulky, offering insights for antiviral drug design.
Area of Science:
- Medicinal Chemistry
- Structural Biology
- Virology
Background:
- Human rhinovirus-14 (HRV-14) is a common cause of the common cold.
- Antiviral drug development requires understanding compound interactions with viral targets.
- Previous studies have explored isoxazole derivatives for antiviral activity.
Purpose of the Study:
- To synthesize and evaluate (oxazolinylphenyl)isoxazoles against HRV-14.
- To determine the binding orientation of active compounds within the HRV-14 capsid protein.
- To develop a structure-activity relationship model based on spatial properties.
Main Methods:
- Synthesis of novel (oxazolinylphenyl)isoxazole compounds.
- Antiviral activity testing using minimum inhibitory concentration (MIC) against HRV-14.
- X-ray crystallography to elucidate compound-protein interactions.
- Computational modeling using van der Waals volume maps.
Main Results:
- Several (oxazolinylphenyl)isoxazoles demonstrated inhibitory activity against HRV-14.
- X-ray crystallography revealed the precise binding orientation of active compounds.
- A predictive model identified excessive bulk around the phenyl ring as a feature of inactive compounds.
- Active compounds preferentially occupied space below the binding site's pore area.
Conclusions:
- Spatial properties, specifically bulk and orientation, are critical for the antiviral efficacy of (oxazolinylphenyl)isoxazoles against HRV-14.
- The developed model can guide the design of more potent HRV-14 inhibitors.
- Understanding binding site topography is key for rational drug design in antiviral research.